Spermosens AB is developing a revolutionary platform technology for diagnosing male-factor infertility and directing to the most suitable infertility treatment.
It has not been possible to predict if the sperms can actually fertilize the oocyte (egg cell). The diagnostics have relied on sperms’ physical properties and motility, thus directing the majority of treatments to the highly invasive and unnecessary ICSI, instead of the safer and more natural standard-IVF.
This all changes now.
Company’s Keywords:
<11
<
<2018